A micro-cap insurance broker reinventing itself as a milestone-funded tech incubator—where upside hinges on Scale51 execution and survival depends on avoiding dilution and delisting.
Reliance Global Group, Inc. (EZRA), headquartered in Lakewood, New Jersey, is a diversified insurance technology (InsurTech) and financial services holding company that has recently undergone a transformative strategic pivot. Founded in August 2013 and listed on the NASDAQ Capital Market, the organization has historically focused on the acquisition and management of wholesale and retail insurance agencies throughout the United States.[1, 2, 3] However, the fiscal year 2025 and the first quarter of 2026 marked a fundamental evolution in the company's business model, shifting from a pure-play insurance broker to a technology incubator and holding company through the launch of its "Scale51" operating model and the EZRA International Group division.[4, 5, 6]
The entity's core operations are currently bifurcated into two primary segments: its legacy insurance brokerage business and its emerging technology growth platform. In the insurance segment, the company generates revenue primarily through commission income derived from the sale of property and casualty (P&C), health, and commercial insurance policies.[7, 8] This revenue is facilitated by two key digital assets: RELI Exchange, a business-to-business (B2B) platform, and 5minuteinsure.com, a business-to-consumer (B2C) portal.[7, 9, 10] RELI Exchange provides independent agents with a comprehensive suite of cloud-based business development tools, comparative rating engines, and lead generation services, allowing them to compete with large-scale national agencies while reducing their internal back-office burdens.[9, 11, 12] In contrast, 5minuteinsure.com leverages artificial intelligence and data mining to offer direct-to-consumer insurance quotes in real-time, targeting the growing demographic of digitally savvy insurance buyers.[7, 9, 13]
The second and increasingly significant segment is the EZRA International Group, which utilizes the "Scale51" model to identify, acquire, and scale high-growth technology companies.[4, 11, 14] Under this framework, the company seeks to acquire majority or controlling stakes (typically 51%) in technology-driven businesses, particularly in sectors such as cybersecurity, artificial intelligence, and digital health.[4, 6, 14] The first major execution of this strategy was the acquisition of Enquantum Ltd., a company specializing in post-quantum cryptography (PQC) designed to protect data against future quantum computing threats.[15, 16, 17] Reliance Global Group's revenue model for this segment is designed to capture value through active ownership and milestone-driven capital allocation, with the ultimate goal of commercializing these technologies in the U.S. market and potentially pursuing subsidiary IPOs or divestitures.[6, 14]
For the fiscal year ended December 31, 2025, the company reported commission income of approximately $12.4 million, a decline from $14.1 million in 2024, reflecting the strategic divestiture of non-core assets such as Fortman Insurance Services, Employee Benefits Solutions, and U.S. Benefits Alliance.[5, 8, 18] Despite the lower top-line figure, the company improved its net loss to $7.0 million from $9.1 million in the previous year and significantly strengthened its balance sheet by reducing long-term debt by 50%.[8, 19, 20] As of March 2026, the company maintains a lean operational structure with approximately 40 employees and continues to prioritize the scaling of its high-margin technology platforms.[8, 21]
| Segment | Primary Products/Services | Customer Base | Revenue Driver |
|---|---|---|---|
| B2B InsurTech | RELI Exchange 2.0 Platform | Independent Insurance Agents | Subscription/Commission Splits [7, 12] |
| B2C InsurTech | 5minuteinsure.com | Individual Consumers | Direct Policy Sales [7, 9] |
| Retail Agencies | Traditional Brokerage | Local Businesses/Individuals | Commission Income [7, 13] |
| EZRA Intl. | Scale51 Technology Holding | Tech Startups (Enquantum) | Equity Appreciation/Licensing [6, 14] |
TRANSITIONAL TECH HOLDING.
The strategic trajectory of Reliance Global Group is currently governed by three primary revenue drivers and growth initiatives: the modernization of the agent ecosystem through RELI Exchange 2.0, the "Scale51" technology acquisition platform, and the "OneFirm" operational integration strategy. Each of these initiatives is designed to transform the company's cost structure and expand its total addressable market (TAM) beyond the traditional insurance brokerage sector.
The most immediate driver of internal growth is the RELI Exchange platform, which provides a scalable infrastructure for independent insurance agents. The company recently launched version 2.0 of this platform in March 2026, which introduces centralized recruiting workflows, integrated task management, and communication tracking.[2, 7, 10] This upgrade is intended to expand the company's recruiting capacity, allowing it to manage a higher volume of agency partners without a proportional increase in corporate headcount.[7, 10, 22] The success of this model is evidenced by the expansion of the broker network from approximately 65 agency partners in 2022 to roughly 300 in early 2026.[2, 7, 23] This network growth directly influences policy volume; health insurance policies written through the platform rose 72% year-over-year in the 2025 enrollment period, while Personal Lines P&C written premiums increased by 36%.[2, 7, 22]
The "Scale51" initiative represents a departure from traditional insurance brokerage. By acquiring 51% controlling interests in technology companies, Reliance Global Group leverages its status as a U.S.-listed entity to provide Israeli and international tech firms with market credibility and access to North American capital and customers.[4, 6, 14] The strategy is "milestone-driven," meaning that capital tranches are released only upon the achievement of specific operational or regulatory goals, which mitigates the risk of large, upfront capital outlays.[16, 17, 24] The acquisition of Enquantum Ltd. is the cornerstone of this segment. Enquantum possesses a 2025 patent for FPGA-based (Field Programmable Gate Array) encrypted communications, which offers hardware-accelerated, quantum-resilient security for high-throughput environments such as telecommunications and financial services.[15, 24] Reliance's management believes that the global shift toward post-quantum encryption standards represents a multi-billion dollar opportunity, positioning EZRA as an early mover in a critical infrastructure niche.[14, 15, 25]
To improve its margin profile, Reliance has implemented the "OneFirm" strategy, which seeks to integrate disparate retail agencies and administrative functions into a single, unified operating unit.[19, 26] This integration is facilitated by the migration of all legacy systems onto the RELI Exchange cloud-based platform, enabling the company to capture economies of scale in marketing, accounting, and compliance.[19, 20] This initiative was a key factor in the company’s ability to divest non-core assets in 2025 while maintaining a viable operational foundation. The sale of Fortman Insurance Services (FIS) for a $3 million gain and the subsequent 50% reduction in long-term debt are direct outcomes of this realignment toward a leaner, more efficient "InsurTech-first" model.[5, 19, 20]
Reliance Global Group's competitive edge is derived from its hybrid nature as an established broker and a technology platform. Unlike pure-play InsurTech startups, Reliance has a "safety net" of cash-flow-positive insurance operations that support its riskier technology investments.[14] Furthermore, the company’s "hands-on" operational involvement distinguishes it from passive venture capital firms.[6, 14] By providing portfolio companies with go-to-market strategies, governance alignment, and U.S. market execution support, Reliance creates a synergistic environment where the parent company's public infrastructure serves as an accelerator for the underlying technologies.[6, 14]
STRATEGIC PIVOT SCALE.
The financial landscape for Reliance Global Group in 2025 was defined by a transition toward a leaner balance sheet and a focus on high-potential technology assets. The year-over-year revenue contraction was a deliberate result of divestitures intended to simplify the organization and eliminate underperforming or high-overhead units.
For the fiscal year ended December 31, 2025, Reliance Global reported commission income of $12.4 million, an 11.6% decrease from the $14.1 million recorded in 2024.[8, 18] This reduction followed the sale of Fortman Insurance Services (FIS), Employee Benefits Solutions, and U.S. Benefits Alliance.[5, 8] The FIS transaction alone generated a $3 million gain in the third quarter of 2025, providing the liquidity necessary to significantly deleverage the business.[19, 20]
| Metric | FY 2025 | FY 2024 | YoY Change |
|---|---|---|---|
| Commission Income | $12.4M | $14.1M | -11.6% [8, 18] |
| Net Loss | ($7.0M) | ($9.1M) | +23.1% (Improv.) [8] |
| Adjusted EBITDA | ($1.6M) | ($0.3M) | -433% [8] |
| Salaries & Wages | $10.3M | $7.2M | +43.1% [8] |
| Unrestricted Cash | $1.3M | $0.4M | +250% [8, 18] |
| Stockholders' Equity | $6.4M | $3.0M | +114% [8] |
| Long-Term Debt | $4.1M | ~$8.2M | -50% [18, 20] |
The deterioration in Adjusted EBITDA to a loss of $1.6 million was primarily driven by the spike in salaries and wages, which management clarified was largely due to non-cash, share-based compensation intended to align executive interests with the new technology focus.[5, 8, 19] General and administrative expenses also rose to $4.1 million, reflecting the costs of the corporate ticker change to "EZRA" and the legal and diligence expenses associated with the Enquantum acquisition.[8, 19, 27]
The company's liquidity position improved significantly in 2025. Unrestricted cash grew by 250% to $1.3 million, and working capital rose by 351% to approximately $1.9 million.[8, 18] The current ratio of 1.78x indicates that the company has sufficient short-term assets to cover its current liabilities.[1, 18] However, the company remains reliant on external financing for its growth initiatives. In early 2026, the company entered into an amended Common Stock Purchase Agreement with White Lion Capital, increasing the potential equity line of credit (ELOC) to $50 million through December 2028.[28, 29, 30] This facility provides a vital liquidity lifeline but also introduces a significant risk of future equity dilution.[31]
As of late March 2026, the market values Reliance Global Group at approximately $3.48 million.[1, 32] This valuation suggests that the company is trading at a steep discount to its net assets and historical sales figures, likely reflecting investor concern over its small market capitalization and historical cash burn.
| Valuation Multiple | EZRA (TTM) | Peer Average | Sector Average |
|---|---|---|---|
| Price / Sales | 0.3x | 2.1x | 2.8x [32] |
| Price / Book Value | 0.5x | 4.3x | 1.0x [32] |
| EV / Revenue | ~0.69x | 3.2x | 3.3x [33] |
| Market Cap / Cash | ~2.6x | N/A | N/A |
The Enterprise Value (EV) of the company is approximately $8.6 million (Market Cap of $3.5M + Debt of $7.1M - Cash of $2.6M, using early 2026 figures).[33, 34] Trading at 0.3x sales compared to an industry average of 2.1x suggests that if the company can stabilize its insurance margins and prove the value of its "Scale51" acquisitions, there is significant theoretical headroom for multiple expansion.[32, 33] However, the market currently treats the tech acquisitions as having zero or negative value, waiting for tangible revenue contributions from Enquantum and other portfolio companies.[15, 33]
UNDERVALUED TRANSITION ASSET.
Investment in Reliance Global Group is subject to a complex array of risks, ranging from immediate listing compliance issues to long-term technological adoption hurdles. As a micro-cap security transitioning its core business model, the margin of error for management is narrow.
The most pressing risk for current shareholders is equity dilution. To fund the "Scale51" acquisitions and general working capital, the company has heavily relied on its equity line of credit with White Lion Capital.[28, 29, 31] In March 2026, the company increased this facility to $50 million.[28, 30] With a total of 21,253,013 common shares outstanding as of March 12, 2026, and a share price of approximately $0.17, the issuance of $50 million worth of stock would result in hundreds of millions of new shares being added to the float.[2, 31] This potential increase in share count could drastically reduce the ownership percentage and earnings per share of existing investors unless the capital raised generates returns that outpace the dilution.[31]
Reliance Global Group's stock price has spent much of the past year trading significantly below the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.[32, 34, 35] While the company has historically utilized reverse stock splits to regain compliance, a failure to maintain the listing would relegate the stock to the OTC markets.[33, 36] A delisting would severely impact the "Scale51" business model, as the company’s primary competitive advantage for target acquisitions—the ability to provide a U.S.-listed platform—would be lost.[14, 33]
The pivot toward high-tech sectors like post-quantum cryptography and AI diagnostics introduces significant execution risk. The acquisition of Enquantum is structured around operational milestones; if these are not met, Reliance may fail to achieve the 51% controlling interest it seeks, potentially stranding its investment.[15, 16, 17] Furthermore, the commercial adoption of quantum-resilient encryption is a multi-year process that depends on international standards and government regulations.[15, 24] Similarly, the proposed acquisition of Scentech Medical remains at the non-binding term sheet stage and is subject to clinical validation and FDA or other regulatory approvals, which are notoriously uncertain and capital-intensive.[37, 38, 39]
The insurance brokerage industry is sensitive to broader economic cycles. Inflationary pressures in 2025 led to higher salaries and wages and increased commission expenses, which partially offset the benefits of the company's debt reduction efforts.[8, 19] Furthermore, a rise in interest rates typically benefits insurance brokers by increasing the yield on fiduciary funds (float), but for a highly leveraged company like Reliance (debt/equity of 0.99x in early 2026), these benefits are often outweighed by higher interest expenses on debt.[1, 27] Geopolitical risks are also relevant, as many of the "Scale51" targets are based in Israel, a region subject to regional volatility that could impact the R&D and operations of portfolio companies like Enquantum and Scentech.[14, 25, 37]
HIGH-RISK STRATEGIC OVERHAUL.
The following five-year projections for Reliance Global Group (EZRA) estimate the potential total return from 2026 through 2031. These scenarios are based on a current share price of $0.17 and a current share count of 21.3 million.[2, 32] A defining assumption in all cases is the use of the White Lion ELOC, which will inevitably lead to share count expansion.[28, 31]
In the base case, the RELI Exchange 2.0 platform succeeds in growing the broker network by 10-15% annually, reaching approximately 500 agency partners by 2031. The "OneFirm" strategy achieves full integration, stabilizing insurance EBITDA margins at 15%. Enquantum completes its commercialization milestones and begins generating licensing revenue by Year 3. The company uses approximately $15 million of the White Lion ELOC over five years, leading to a share count of 120 million.
The high case assumes the RELI Exchange becomes a dominant InsurTech platform, with the agent network growing to over 700 partners. Enquantum secures multiple contracts with Tier-1 telecommunications carriers, and Scentech Medical receives regulatory clearance for its AI diagnostic products, driving significant royalty income. The company successfully manages dilution by raising capital at progressively higher share prices, resulting in a 5-year share count of 80 million.
The low case assumes the tech acquisitions fail to achieve milestones, and the investment capital is eventually impaired. Insurance revenue continues to decline as agents migrate to better-capitalized competitors. The company is forced to draw on the entire $50 million ELOC at low share prices to fund operations, leading to a massive dilution of 400 million shares. The stock eventually undergoes multiple reverse splits and is delisted from the Nasdaq.
| Scenario | Year 1 (2027) | Year 2 (2028) | Year 3 (2029) | Year 4 (2030) | Year 5 (2031) |
|---|---|---|---|---|---|
| High Case | $0.60 | $1.25 | $2.10 | $2.80 | $3.52 |
| Base Case | $0.20 | $0.25 | $0.28 | $0.32 | $0.37 |
| Low Case | $0.08 | $0.04 | $0.02 | $0.01 | $0.01 |
| Scenario | Subjective Probability | 5-Year Target Price | Weighted Value |
|---|---|---|---|
| High Case | 10.0% | $3.52 | $0.352 |
| Base Case | 45.0% | $0.37 | $0.167 |
| Low Case | 45.0% | $0.01 | $0.005 |
| Total Weighted Target | 100.0% | $0.524 |
The probability-weighted target of $0.52 suggests a potential upside from the current $0.17 price, but the high probability assigned to the low case reflects the binary nature of the company's current transition strategy.
HIGH-STAKES OPTION PLAY.
Alignment is a dual-edged sword for Reliance Global. On the positive side, CEO Ezra Beyman has demonstrated conviction through open-market purchases (e.g., 300,000 shares in March 2026) and the use of his personal entities to settle legacy disputes.[2, 28] However, the total compensation for executive officers in 2025—$2.48 million for the CEO and $1.11 million for the CFO—is extremely high relative to the company’s $3.5 million market capitalization.[1, 31] Furthermore, the CFO, Joel Markovits, has been a net seller in 2026, which can be interpreted as a lack of confidence in near-term price appreciation.[2]
The insurance commission revenue is inherently recurring and stable, forming a solid base for the company.[9, 14] However, the recent 11.6% revenue decline due to divestitures and the loss of the Fortman client base has weakened the quality of the immediate top line.[8, 19] The shift toward high-tech "Scale51" revenue is currently theoretical and lacks the established track record of the legacy brokerage segment.[14, 15]
Reliance is a minor player in the broader insurance brokerage market but is winning share within its niche of providing digital tools to independent agents.[9, 12] The expansion of the broker network from 65 to 300 partners suggests strong adoption of the RELI Exchange product.[2, 7] However, in the cybersecurity space, Enquantum is an unproven startup competing against massive incumbents.[15, 33]
The mathematical growth potential is substantial because the company is starting from such a small market capitalization. The transition into the $300 billion post-quantum cryptography market and the multi-billion dollar AI diagnostic market via Scentech Medical offers an outlook that is far superior to traditional insurance brokerage growth.[25, 37]
Despite the 2025 debt reduction, the company remains financially fragile. The high cash burn rate, negative Adjusted EBITDA ($1.6M loss), and the reliance on a dilutive ELOC to fund "Scale51" milestones indicate a weak financial health score.[8, 32, 35] The current ratio of 1.78 is the only major bright spot in the liquidity profile.[1, 18]
The insurance brokerage business is durable and viable over the long term, as risk management is a non-discretionary expense for most businesses.[12] However, the viability of the parent company as a publicly traded entity is at risk due to persistent Nasdaq non-compliance and the potential for delisting.[33, 40]
Management has shown discipline in divesting lower-margin, high-overhead non-core assets to pay down 50% of the company's debt.[5, 19, 20] The "milestone-based" approach to the Enquantum acquisition is also a prudent way to deploy limited capital.[16, 17] However, the high executive salaries represent a drag on capital that could be used for R&D.[31]
There is virtually no institutional analyst coverage of EZRA in the 2025-2026 period.[41, 42] Technical indicators and sentiment trackers (e.g., Fear & Greed Index at 39) generally remain in the "Bearish" or "Strong Sell" categories.[33, 43]
The company is fundamentally unprofitable on an operating and net basis.[2, 18] The operating margin of -72.5% is significantly below industry standards, and the 2025 improvement in net loss was largely due to one-time gains from asset sales rather than organic profit generation.[8, 18, 19]
The long-term track record of shareholder value creation is poor, with the stock price down over 80% in the past year and significantly more over a five-year period.[32, 34, 35] While the "Scale51" pivot is a logical attempt to reset the narrative, it has yet to yield tangible financial results for investors.[33, 41]
OVERALL BLENDED SCORE: 4.4/10
DISTRUSTFUL SPECULATIVE TRANSFORMATION.
Reliance Global Group (EZRA) is currently a dual-track enterprise consisting of a stabilizing, cloud-enabled insurance brokerage and a high-risk venture holding company. The investment thesis for the organization centers on the successful execution of the "Scale51" model, where the company uses its public platform to accelerate high-potential technology firms like Enquantum. The 50% reduction in long-term debt and the successful launch of RELI Exchange 2.0 in early 2026 demonstrate that management is capable of streamlining operations and delivering on product roadmaps.[7, 19, 20] The growth of the agent network to 300 partners provides a legitimate foundation of commission revenue that supports the corporate overhead.[2, 7, 12]
However, the path forward is fraught with systemic risks. The $50 million ELOC with White Lion Capital is a "poisoned chalice" that provides necessary capital at the cost of massive equity dilution, potentially capping any significant share price appreciation unless the acquired technologies reach scale with unprecedented speed.[28, 31] The company must also navigate the regulatory and commercialization gauntlet for Enquantum and Scentech Medical, which are non-core businesses for a management team historically focused on insurance.[15, 37, 38]
Key Catalysts:
* Enquantum Commercialization: Signing of a definitive partnership or pilot program with a North American telecommunications carrier.[25]
* Scentech Acquisition Closure: Moving the Scentech deal from a non-binding term sheet to a definitive agreement would validate the "Scale51" pipeline.[37, 38]
* Nasdaq Compliance: Regaining the $1.00 minimum bid price would remove the immediate delisting threat and attract a broader investor class.[33, 40]
In summary, EZRA is a speculative turnaround story. Investors are essentially buying an option on the future of quantum cryptography and AI diagnostics, packaged within a micro-cap insurance shell. The potential for exponential gains is real, but it is balanced by a high probability of further dilution or operational failure.
SPECULATIVE TECH OPTION.
Reliance Global Group's stock price is currently in a sustained downtrend, trading near its 52-week low of $0.15 and well below the 200-day moving average of $0.82-$0.84.[34, 44] The recent launch of RELI Exchange 2.0 and the completion of the first Enquantum milestone have failed to spark a durable rally, as the market remains concerned about the dilution from the White Lion ELOC.[2, 28, 31] Technical indicators such as the RSI(14) at 22 and Williams %R at -96 indicate that the stock is in an "Oversold" state, suggesting a short-term relief bounce is possible.[43, 45] However, the short-term outlook remains bearish until the company can demonstrate a definitive move toward breakeven or announce a major commercial contract for its technology portfolio.
BEARISH OVERSOLD STATE.
View Reliance Global Group, Inc. (EZRA) stock page
Loading the interactive version of this report…